title: Crizotinib as salvage and maintenance with allogeneic stem cell transplantation for refractory anaplastic large cell lymphoma.
abstract: The NPM-ALK fusion protein is found in ALK(+) anaplastic large cell lymphomas harboring the t(2;5) chromosomal translocation. Patients harboring ALK translocations typically have an excellent prognosis with conventional chemotherapy and a reported 5-year survival rate of 70%. Although most patients with ALK(+) anaplastic large cell lymphoma have a good prognosis, some patients do not respond to standard therapies. In patients with refractory anaplastic large cell lymphoma who can achieve remission, allogeneic stem cell transplant is a potentially curative option. This article describes a patient with refractory ALK(+) anaplastic large cell lymphoma who experienced a complete response to the ALK inhibitor crizotinib and then underwent an allogeneic stem cell transplant followed by crizotinib maintenance therapy.
authors.affiliation: From aDana-Farber Cancer Institute, Harvard Medical School and bBrigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; cUniversity of Rochester Medical Center, University of Rochester, Rochester, New York; and dMassachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
authors.forename: James M
authors.initials: JM
authors.lastname: Cleary
authors.forename: Scott
authors.initials: S
authors.lastname: Rodig
authors.forename: Paul M
authors.initials: PM
authors.lastname: Barr
authors.forename: Atul B
authors.initials: AB
authors.lastname: Shinagare
authors.forename: Jeffrey W
authors.initials: JW
authors.lastname: Clark
authors.forename: Geoffrey I
authors.initials: GI
authors.lastname: Shapiro
authors.forename: Philippe
authors.initials: P
authors.lastname: Armand
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000077547:Crizotinib; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D017728:Lymphoma, Large-Cell, Anaplastic / Q000175:diagnosis / Q000628:therapy*; D060046:Maintenance Chemotherapy; D008297:Male; D049268:Positron-Emission Tomography; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011720:Pyrazoles / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D016879:Salvage Therapy; D014057:Tomography, X-Ray Computed; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib